{"id":835,"date":"2021-12-27T12:32:42","date_gmt":"2021-12-27T11:32:42","guid":{"rendered":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/?p=835"},"modified":"2021-12-27T12:32:42","modified_gmt":"2021-12-27T11:32:42","slug":"sobre-trastorns-oculars-per-farmacs-carrega-anticolinergica-i-us-de-biologics-per-acabar-lany","status":"publish","type":"post","link":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/sobre-trastorns-oculars-per-farmacs-carrega-anticolinergica-i-us-de-biologics-per-acabar-lany\/","title":{"rendered":"Sobre trastorns oculars per f\u00e0rmacs, c\u00e0rrega anticolin\u00e8rgica i \u00fas de biol\u00f2gics per acabar l&#8217;any"},"content":{"rendered":"<p>Per tancar l\u2019any 2021 hem seleccionat uns quants butlletins que ens apropen, de manera sint\u00e8tica, a diversos temes rellevants per a la pr\u00e0ctica assistencial di\u00e0ria:<\/p>\n<p><img loading=\"lazy\" class=\"alignnone size-medium wp-image-236 alignleft\" src=\"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2019\/01\/Captura_1-1-300x107.png\" alt=\"\" width=\"300\" height=\"107\" srcset=\"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2019\/01\/Captura_1-1-300x107.png 300w, http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2019\/01\/Captura_1-1.png 461w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>El <a href=\"https:\/\/scientiasalut.gencat.cat\/bitstream\/handle\/11351\/6490\/BFV_2021_19_04_ca.pdf?sequence=1&amp;isAllowed=y\">Butllet\u00ed de Farmacovigil\u00e0ncia de Catalunya<\/a> revisa els efectes adversos oculars per f\u00e0rmacs d\u2019administraci\u00f3 oral. Tal com comenten els autors del butllet\u00ed: \u201cL\u2019abundant vascularitzaci\u00f3 i la massa relativament petita de l\u2019ull el fa susceptible a l\u2019aparici\u00f3 d\u2019efectes adversos oculars associats a l\u2019\u00fas d\u2019alguns f\u00e0rmacs. S\u2019hi poden veure afectades diverses parts de l\u2019ull i experimentar s\u00edmptomes caracter\u00edstics de trastorns oculars espec\u00edfics. Quan un pacient presenta un s\u00edmptoma ocular de causa inexplicable, cal fer una anamnesi farmacol\u00f2gica acurada\u201d.<\/p>\n<p style=\"text-align: left\"><img loading=\"lazy\" class=\"alignnone  wp-image-836 alignright\" src=\"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2021\/12\/infac-farmacoerapeutica-es-300x66.jpg\" alt=\"\" width=\"341\" height=\"75\" srcset=\"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2021\/12\/infac-farmacoerapeutica-es-300x66.jpg 300w, http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2021\/12\/infac-farmacoerapeutica-es-768x170.jpg 768w, http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2021\/12\/infac-farmacoerapeutica-es-1024x226.jpg 1024w, http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2021\/12\/infac-farmacoerapeutica-es.jpg 1031w\" sizes=\"(max-width: 341px) 100vw, 341px\" \/>El <a href=\"https:\/\/www.euskadi.eus\/contenidos\/informacion\/cevime_infac_2021\/es_def\/adjuntos\/INFAC__Vol-29-n-8-Medicamentos-biologicos.pdf\"><em>Bolet\u00edn de Informaci\u00f3n Farmacoterap\u00e9utica INFAC<\/em> <\/a>del Pa\u00eds Basc, publiquen una revisi\u00f3 sint\u00e8tica i actualitzada sobre alguns aspectes relacionats amb els medicaments biol\u00f2gics indicats a la profilaxi de la migranya, a les hiperlip\u00e8mies i a l&#8217;asma, patologies inicialment diagnosticades i tractades en atenci\u00f3 prim\u00e0ria, per\u00f2 que a estadis m\u00e9s greus es tracten en atenci\u00f3 especialitzada. Encara que s\u00f3n medicaments de prescripci\u00f3 i dispensaci\u00f3 exclusivament hospital\u00e0ria, pot resultar d\u2019inter\u00e8s per als metges d\u2019atenci\u00f3 prim\u00e0ria con\u00e8ixer-ne les caracter\u00edstiques generals, efectes secundaris i lloc en terap\u00e8utica. Alirocumab, evolocumab, erenumab, galcanezumab, omalizumab, benralizumab, etc&#8230;s\u00f3n noms que ens resultaran cada cop m\u00e9s familiars per casos greus que no responen o no toleren les opcions terap\u00e8utiques de primeres l\u00ednies.<\/p>\n<p><img loading=\"lazy\" class=\"alignright\" src=\"https:\/\/cadime.es\/images\/logo_cadime_.svg\" width=\"138\" height=\"158\" \/>El <a href=\"https:\/\/cadime.es\/bta\/bta\/869-carga-anticolin%C3%A9rgica-recomendaciones.html\"><em>Bolet\u00edn terap\u00e9utico andaluz (CADIME)<\/em>,<\/a> publica un n\u00famero sobre una q\u00fcesti\u00f3 sempre important: La c\u00e0rrega anticolin\u00e8rgica i els riscos associats, entenent l&#8217;efecte acumulatiu de prendre un o m\u00e9s medicaments que\u00a0poden desenvolupar efectes anticolin\u00e8rgics adversos. La quantificaci\u00f3 \u00e9s essencial en pacients d&#8217;edat<br \/>\navan\u00e7ada (sobretot en els m\u00e9s vulnerables) per avaluar el risc anticolin\u00e8rgic i adoptar les mesures\u00a0necess\u00e0ries per reduir-lo. Una revisi\u00f3 fonamental.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Per tancar l\u2019any 2021 hem seleccionat uns quants butlletins que ens apropen, de manera sint\u00e8tica, a diversos temes rellevants per a la pr\u00e0ctica assistencial di\u00e0ria: El Butllet\u00ed de Farmacovigil\u00e0ncia de Catalunya revisa els efectes adversos oculars per f\u00e0rmacs d\u2019administraci\u00f3 oral. &hellip; <a href=\"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/sobre-trastorns-oculars-per-farmacs-carrega-anticolinergica-i-us-de-biologics-per-acabar-lany\/\">Continua llegint <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[19],"tags":[874,872,120,684,870,880,242,878,868,699,876,416],"_links":{"self":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/posts\/835"}],"collection":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/comments?post=835"}],"version-history":[{"count":1,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/posts\/835\/revisions"}],"predecessor-version":[{"id":837,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/posts\/835\/revisions\/837"}],"wp:attachment":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/media?parent=835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/categories?post=835"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/tags?post=835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}